SGLT 2 INHIBITORS | Latest News RSS feed

SGLT 2 INHIBITORS - Latest News


Novel Use of SGLT-2 Inhibitors for Treatment of Early-Stage Lung Adenocarcinoma

Study assessed association of cancer and sodium glucose transporter 2 expression as well as potential benefit of SGLT-2 treatment. The leading cause of cancer-related mortality is a variant of lung ca... read more

SGLT2 Inhibitors: Is This the Start of a New Era?

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a relatively new class of antihyperglycemic agents that lower blood glucose by enhancing urinary excretion of glucose. [1] This mechanism of actio... read more

3 Ways Taking an SGLT2 Inhibitor Has Changed How I Manage Diabetes

Last month my endocrinologist asked if I would consider adding Jardiance (empagliflozin) to my diabetes management routine of Glucophage (metformin) twice per day. She explained that it was one availa... read more

Looking for another news?


SGLT2 Inhibitors Market Trends Shows a Rapid Growth by 2024

Albany, NY -- (SBWIRE) -- 12/12/2018 -- Sodium glucose transporters are proteins responsible for reabsorption of glucose from kidneys. This protein family has two members: sodium glucose cotransporter ... read more


Sirona Biochem's SGLT2 Inhibitor in Testing for Animal Health

VANCOUVER, Dec. 11, 2018 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") announced today that testing has commenced for the SGLT2 inhibitor, TFC-039, in cats. Several months ago, ... read more

ACC Releases Consensus Decision Pathway for CVD Risk Reduction in T2D and ASCVD

Examples of SGLT2 inhibitor drugs include empagliflozin and canagliflozin, both of which may reduce major adverse cardiac events (MACE) as well as heart failure hospitalization. The EMPA-REG OUTCOME ( ... read more

Glenmark Pharmaceuticals rating ‘buy’: Domestic growth to stand out

GNP has a strong record of new launches, and in this report we assess the launch of its SGLT2 inhibitor. We expect the product to cross Rs 2 bn in sales in FY22F (in a Rs 20 bn market), and be the key ... read more

Higher risk for amputation, DKA with SGLT2 inhibitors for T2DM

(HealthDay)—Use of sodium glucose cotransporter 2 (SGLT2) inhibitors is associated with an increased risk for lower-limb amputation and diabetic ketoacidosis compared with use of glucagon-like peptide ... read more

Certain SGLT2 Inhibitors, GLP-1 RAs for T2DM Also Cut CV Risk

(HealthDay News) — Certain sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) demonstrate significant cardiovascular (CV) benefit and should be ... read more

Certain Diabetes Meds Tied to Higher Odds for Amputation

People on sodium-glucose cotransporter2 (SGLT2) inhibitors were twice as likely to require a lower limb amputation as people taking another type of diabetes medication, Scandinavian researchers found. ... read more

Serious Adverse Events Compared With SGLT2 Inhibitors, GLP1 Receptor Agonists

(HealthDay News) — Use of sodium glucose cotransporter 2 (SGLT2) inhibitors is associated with an increased risk for lower-limb amputation and diabetic ketoacidosis compared with use of glucagon-like ... read more

Researchers identify a mechanism that fuels cancer cells' growth

They were able to use SGLT2 activity to monitor the effects of SGLT2 inhibitors to treat mice with genetic models of lung cancer and mice that had been implanted with human lung tumors. read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us